Stock Analysis on Net
Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Danaher Corp., historical price multiples (quarterly data)

Microsoft Excel
Jun 26, 2026 Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Price to earnings (P/E) 31.43 37.32 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Price to operating profit (P/OP) 24.54 28.93 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Price to sales (P/S) 5.01 5.56 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Price to book value (P/BV) 2.39 2.60 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36

Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


The valuation metrics exhibit a period of significant volatility characterized by a sharp expansion in multiples during 2024, followed by a comprehensive contraction through mid-2026.

Earnings and Operating Profit Multiples
The Price to Earnings (P/E) and Price to Operating Profit (P/OP) ratios show highly correlated movements. Both ratios experienced a decline through early 2023, with the P/E reaching a local low of 24.76 in September 2023. This was followed by a rapid valuation expansion, peaking in September 2024 at 48.49 for P/E and 39.52 for P/OP. Subsequently, a normalization phase occurred, leading to a P/E of 31.43 and a P/OP of 24.54 by June 2026.
Revenue Valuation
The Price to Sales (P/S) ratio remained relatively stable between 5.63 and 6.77 from April 2022 through September 2023. A peak was observed in June 2024 at 8.10, aligning with the broader valuation spike seen in earnings multiples. However, the ratio entered a sustained decline thereafter, reaching a period low of 5.01 by June 2026, indicating a reduction in the premium attributed to each unit of revenue.
Book Value Compression
The Price to Book Value (P/BV) ratio demonstrates a consistent long-term downward trajectory. Starting at a peak of 4.36 in early 2022, the ratio declined steadily, with only minor fluctuations, before finishing at its lowest point of 2.39 in June 2026. This suggests a persistent compression of the market's valuation relative to the company's net asset value over the analyzed timeframe.

AI Ask an analyst for more



Price to Earnings (P/E)

Danaher Corp., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 26, 2026 Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1 702,986,054 707,770,627 707,139,356 706,349,563 716,051,590 715,669,594 714,709,852 722,275,141 722,213,081 740,686,541 739,701,725 738,927,107 738,352,114 737,898,789 728,576,886 727,962,702 727,445,355 727,076,766
Selected Financial Data (US$)
Net earnings attributable to common stockholders (in millions) 870 1,029 1,197 908 555 954 1,086 818 907 1,088 1,079 1,129 1,106 1,429 2,210 1,551 1,658 1,684
Earnings per share (EPS)2 5.70 5.21 5.11 4.96 4.77 5.26 5.46 5.39 5.82 5.94 6.41 7.95 8.53 9.28 9.75 9.12 8.53 8.65
Share price1, 3 179.01 194.54 209.19 220.77 189.91 192.07 207.95 261.28 264.18 253.11 250.65 196.84 255.70 231.99 250.11 243.08 279.23 278.24
Valuation Ratio
P/E ratio4 31.43 37.32 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 97.96 94.06 159.78 92.57 77.73 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64
Amgen Inc. 22.82 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Bristol-Myers Squibb Co. 14.27 17.01 17.30 15.38 17.46 18.29 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64
Eli Lilly & Co. 34.82 47.45 43.36 43.95 67.76 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29
Gilead Sciences Inc. 18.06 21.54 18.18 21.68 20.62 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25
Johnson & Johnson 29.70 25.87 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Merck & Co. Inc. 31.27 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Pfizer Inc. 20.12 19.83 14.06 13.09 17.22 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Regeneron Pharmaceuticals Inc. 17.56 16.27 18.19 15.03 13.29 13.65 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15
Thermo Fisher Scientific Inc. 25.46 28.82 32.45 26.56 24.55 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15
Vertex Pharmaceuticals Inc. 24.83 31.58 29.11 26.43 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50

Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
EPS = (Net earnings attributable to common stockholdersQ2 2026 + Net earnings attributable to common stockholdersQ1 2026 + Net earnings attributable to common stockholdersQ4 2025 + Net earnings attributable to common stockholdersQ3 2025) ÷ No. shares of common stock outstanding
= (870,000,000 + 1,029,000,000 + 1,197,000,000 + 908,000,000) ÷ 702,986,054 = 5.70

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/E ratio = Share price ÷ EPS
= 179.01 ÷ 5.70 = 31.43

5 Click competitor name to see calculations.


The financial trajectory from April 2022 through June 2026 is characterized by a significant contraction in earnings per share and a fluctuating valuation multiple, resulting in an overall decline in share price.

Earnings Per Share (EPS) Trends
A sustained downward trend in profitability is observed, beginning after a peak of 9.75 USD in December 2022. EPS declined steadily over the following two years, reaching a trough of 4.77 USD in June 2025. This represents a substantial reduction in bottom-line performance. A moderate recovery period emerged in the final three quarters, with EPS rising back to 5.70 USD by June 2026.
Share Price Movement
The share price exhibited an overall bearish trend, declining from 278.24 USD in April 2022 to 179.01 USD by June 2026. Although periods of temporary appreciation occurred—most notably reaching 264.18 USD in June 2024—these gains were not sustained, and the price trended lower in alignment with the diminishing earnings profile.
Price to Earnings (P/E) Ratio Analysis
The P/E ratio experienced three distinct phases. From April 2022 to September 2023, the ratio remained relatively stable, oscillating between 24.76 and 32.73. A period of significant valuation expansion followed, with the P/E ratio climbing sharply to a peak of 48.49 in September 2024; this indicates that the market maintained a high valuation multiple despite the concurrent decline in EPS. In the final phase, from December 2024 to June 2026, the ratio underwent a contraction, returning to 31.43 as the valuation realigned with the company's earnings performance.

AI Ask an analyst for more



Price to Operating Profit (P/OP)

Danaher Corp., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 26, 2026 Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1 702,986,054 707,770,627 707,139,356 706,349,563 716,051,590 715,669,594 714,709,852 722,275,141 722,213,081 740,686,541 739,701,725 738,927,107 738,352,114 737,898,789 728,576,886 727,962,702 727,445,355 727,076,766
Selected Financial Data (US$)
Operating profit (in millions) 1,127 1,344 1,502 1,154 760 1,274 1,425 958 1,168 1,312 1,337 1,185 1,163 1,517 2,296 2,015 2,205 2,172
Operating profit per share2 7.29 6.73 6.63 6.53 6.17 6.74 6.80 6.61 6.93 6.75 7.03 8.34 9.47 10.89 11.92 11.74 10.78 10.51
Share price1, 3 179.01 194.54 209.19 220.77 189.91 192.07 207.95 261.28 264.18 253.11 250.65 196.84 255.70 231.99 250.11 243.08 279.23 278.24
Valuation Ratio
P/OP ratio4 24.54 28.93 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 23.23 26.37 42.20 31.76 32.37 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57
Amgen Inc. 16.84 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Bristol-Myers Squibb Co. 11.30 12.42 12.20 10.25 11.07 13.65 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32
Eli Lilly & Co. 27.92 37.24 34.60 35.19 53.43 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49
Gilead Sciences Inc. 16.05 18.29 14.06 17.00 14.96 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78
Johnson & Johnson 24.10 21.40 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Merck & Co. Inc. 23.37 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Pfizer Inc. 10.37 10.82 10.07 9.49 11.27 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Regeneron Pharmaceuticals Inc. 19.78 19.83 22.90 18.65 15.42 16.03 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98
Thermo Fisher Scientific Inc. 22.09 24.94 28.40 23.62 21.64 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84
Vertex Pharmaceuticals Inc. 23.01 29.92 26.79 24.50 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13

Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
Operating profit per share = (Operating profitQ2 2026 + Operating profitQ1 2026 + Operating profitQ4 2025 + Operating profitQ3 2025) ÷ No. shares of common stock outstanding
= (1,127,000,000 + 1,344,000,000 + 1,502,000,000 + 1,154,000,000) ÷ 702,986,054 = 7.29

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 179.01 ÷ 7.29 = 24.54

5 Click competitor name to see calculations.


An analysis of the financial metrics from April 2022 through June 2026 reveals a period of significant volatility in valuation multiples, primarily driven by a sustained decline in operating profitability per share and fluctuating market pricing.

Operating Profit Per Share Trends
A general downward trajectory in operating profit per share is evident, peaking at 11.92 USD in December 2022 before descending to a low of 6.17 USD by June 2025. This represents a substantial contraction in per-share operational efficiency over the observed period. However, a recovery phase began in late 2025, with the figure rising to 7.29 USD by June 2026.
Price to Operating Profit (P/OP) Valuation
The P/OP ratio experienced three distinct phases. Initially, the ratio compressed from 26.48 in April 2022 to a low of 20.71 by September 2022. This was followed by a period of aggressive valuation expansion, where the ratio climbed steadily to a peak of 39.52 in September 2024. In the final phase, the ratio underwent a corrective contraction, falling back to 24.54 by June 2026.
Correlation Between Price and Profitability
The spike in the P/OP ratio during 2023 and 2024 was primarily driven by the fact that operating profit per share declined more rapidly than the share price. Between December 2023 and September 2024, the share price remained relatively resilient or increased, while operating profit per share continued to erode, thereby inflating the valuation multiple. The subsequent decline in the P/OP ratio through 2025 and 2026 reflects a realignment, as the share price declined further while operating profits began to stabilize and recover.

Overall, the data indicates a transition from a period of high valuation premiums relative to operating performance back toward a valuation baseline consistent with early 2022 levels.

AI Ask an analyst for more



Price to Sales (P/S)

Danaher Corp., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 26, 2026 Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1 702,986,054 707,770,627 707,139,356 706,349,563 716,051,590 715,669,594 714,709,852 722,275,141 722,213,081 740,686,541 739,701,725 738,927,107 738,352,114 737,898,789 728,576,886 727,962,702 727,445,355 727,076,766
Selected Financial Data (US$)
Sales (in millions) 6,265 5,951 6,838 6,053 5,936 5,741 6,538 5,798 5,743 5,796 6,405 5,624 5,912 5,949 8,369 7,663 7,751 7,688
Sales per share2 35.71 35.01 34.74 34.36 33.54 33.28 33.41 32.87 32.63 32.05 32.30 34.99 37.78 40.29 43.20 42.93 42.36 41.65
Share price1, 3 179.01 194.54 209.19 220.77 189.91 192.07 207.95 261.28 264.18 253.11 250.65 196.84 255.70 231.99 250.11 243.08 279.23 278.24
Valuation Ratio
P/S ratio4 5.01 5.56 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 5.67 6.50 6.40 5.97 5.68 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76
Amgen Inc. 5.02 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Bristol-Myers Squibb Co. 2.69 2.55 2.53 1.93 1.85 2.08 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41
Eli Lilly & Co. 12.18 15.03 13.44 11.39 15.36 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47
Gilead Sciences Inc. 5.69 6.34 5.16 4.76 4.31 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86
Johnson & Johnson 6.38 5.65 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Merck & Co. Inc. 4.25 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Pfizer Inc. 2.38 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Regeneron Pharmaceuticals Inc. 4.89 4.82 5.71 4.83 4.17 4.36 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40
Thermo Fisher Scientific Inc. 3.86 4.34 4.87 4.05 3.73 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20
Vertex Pharmaceuticals Inc. 8.82 10.40 9.13 8.42 10.41 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17

Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
Sales per share = (SalesQ2 2026 + SalesQ1 2026 + SalesQ4 2025 + SalesQ3 2025) ÷ No. shares of common stock outstanding
= (6,265,000,000 + 5,951,000,000 + 6,838,000,000 + 6,053,000,000) ÷ 702,986,054 = 35.71

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 179.01 ÷ 35.71 = 5.01

5 Click competitor name to see calculations.


The Price-to-Sales (P/S) ratio for Danaher Corp. exhibits significant volatility over the analyzed period, characterized by a series of peaks and troughs that reflect shifting market valuations relative to revenue performance.

Valuation Volatility and Peak Analysis
The P/S ratio fluctuated between a low of 5.01 and a high of 8.10. An initial contraction is observed in 2022, where the ratio fell from 6.68 in April to 5.66 by September. This was followed by a period of instability in 2023, culminating in a sharp valuation expansion that peaked at 8.10 in June 2024. This peak was primarily driven by a recovery in share price to 264.18 US$ while sales per share remained relatively low at 32.63 US$, indicating a period of high market optimism or speculative pricing relative to actual revenue.
Revenue per Share Trends
Sales per share showed a general downward trajectory from April 2022 (41.65 US$) through March 2024, reaching a trough of 32.05 US$. Following this period, a gradual recovery in revenue generation is evident, with sales per share increasing steadily to 35.71 US$ by June 2026. Despite this modest recovery in fundamental sales performance, the share price did not maintain a corresponding upward trajectory.
Long-term Valuation Contraction
A sustained downward trend in the P/S ratio is observable from June 2024 through June 2026. The ratio declined from its peak of 8.10 to a period low of 5.01. This compression is attributed to a significant decline in share price, which fell from 264.18 US$ in June 2024 to 179.01 US$ by June 2026. The fact that the P/S ratio reached its lowest point in the series despite improving sales per share suggests a fundamental reassessment of the company's valuation multiple by the market.

Overall, the data indicates a decoupling of share price and sales performance. While revenue per share began to recover in the latter half of the period, the market valuation contracted, leading to a significantly lower P/S multiple by mid-2026.

AI Ask an analyst for more



Price to Book Value (P/BV)

Danaher Corp., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 26, 2026 Mar 27, 2026 Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1 702,986,054 707,770,627 707,139,356 706,349,563 716,051,590 715,669,594 714,709,852 722,275,141 722,213,081 740,686,541 739,701,725 738,927,107 738,352,114 737,898,789 728,576,886 727,962,702 727,445,355 727,076,766
Selected Financial Data (US$)
Total Danaher stockholders’ equity (in millions) 52,581 52,949 52,534 51,071 52,334 50,849 49,543 51,299 49,897 53,442 53,486 52,407 51,716 51,478 50,082 46,985 46,594 46,356
Book value per share (BVPS)2 74.80 74.81 74.29 72.30 73.09 71.05 69.32 71.02 69.09 72.15 72.31 70.92 70.04 69.76 68.74 64.54 64.05 63.76
Share price1, 3 179.01 194.54 209.19 220.77 189.91 192.07 207.95 261.28 264.18 253.11 250.65 196.84 255.70 231.99 250.11 243.08 279.23 278.24
Valuation Ratio
P/BV ratio4 2.39 2.60 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 229.63 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59
Amgen Inc. 19.37 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87
Bristol-Myers Squibb Co. 5.94 6.17 6.61 5.01 5.06 5.70 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07
Eli Lilly & Co. 28.21 36.91 33.55 33.19 47.74 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75
Gilead Sciences Inc. 7.08 8.07 6.85 6.96 6.42 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91
Johnson & Johnson 7.35 6.70 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36
Merck & Co. Inc. 6.09 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44
Pfizer Inc. 1.67 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37
Regeneron Pharmaceuticals Inc. 2.40 2.29 2.62 2.22 1.98 2.09 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65
Thermo Fisher Scientific Inc. 3.36 3.62 4.18 3.46 3.24 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23
Vertex Pharmaceuticals Inc. 5.56 6.69 6.18 5.60 7.01 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95

Based on: 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
BVPS = Total Danaher stockholders’ equity ÷ No. shares of common stock outstanding
= 52,581,000,000 ÷ 702,986,054 = 74.80

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 179.01 ÷ 74.80 = 2.39

5 Click competitor name to see calculations.


An analysis of the valuation metrics between April 2022 and June 2026 reveals a significant contraction in the Price-to-Book Value (P/BV) ratio, driven primarily by a decline in market share price despite a steady increase in the underlying book value per share.

Price-to-Book Value (P/BV) Ratio Trend
The P/BV ratio exhibits a clear long-term downward trajectory, starting at a peak of 4.36 in early 2022 and declining to a period low of 2.39 by June 2026. While there were temporary recoveries—most notably in mid-2024 when the ratio climbed back to 3.82—the overall trend indicates a narrowing premium that the market is willing to assign to the company's net asset value.
Book Value per Share (BVPS) Growth
In contrast to the volatile share price, the Book Value per Share demonstrates consistent and stable growth. BVPS rose from 63.76 US$ in April 2022 to 74.80 US$ by June 2026. This represents a steady accumulation of equity and a strengthening of the company's fundamental accounting value over the analyzed period.
Share Price Volatility and Valuation Impact
The compression of the P/BV ratio is directly attributable to the downward pressure on the share price. The market price peaked at 279.23 US$ in July 2022 and reached a low of 179.01 US$ in June 2026. Because the share price declined while the book value increased, the resulting P/BV ratio dropped sharply, particularly in the period between December 2024 and June 2026.
Correlation Analysis
A divergence is observed between the company's intrinsic accounting growth and its market valuation. The steady climb in BVPS suggests operational stability or capital accumulation, yet the falling P/BV ratio suggests a shift in investor sentiment or a broader market re-rating of the company's valuation multiples.

AI Ask an analyst for more